Is There a Role for Induction Chemotherapy in the Treatment of Advanced Head and Neck Cancer?
Treatment of squamous cell carcinoma of the head and neck (HNSCC) requires a multimodality approach on many occasions requiring a combination of surgery, radiation and chemotherapy. Surgery and radiation are mainstays in the definitive treatment of HSNCC, but the last two decades have seen treatment focused on organ preservation with a combination of chemotherapy and radiation. However, the role of chemotherapy and its timing is controversial. The initial hypothesis that chemotherapy in the induction setting would reduce metastatic burden did not result in survival benefit and is no longer advised in standard treatment. However, newer chemotherapy agents and dose regimens have led to a renewed interest for induction regimens. This chapter summarizes the key data that study the use of induction chemotherapy in HNSCC with a focus on phase III randomized trials.
KeywordsTPF TAX 324 Induction chemotherapy Neoadjuvant therapy Meta-analysis of chemotherapy Organ preservation
- 6.Blanchard P, Bourhis J, Lacas B, et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol. 2013;31:2854–60.CrossRefGoogle Scholar
- 11.Haddad R, O’Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013;14:257–64.CrossRefGoogle Scholar
- 19.Yang H, Chen X, Lin S, et al. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a prospective, multi-center, randomized clinical trial. Radiother Oncol. 2018;126:37–42.CrossRefGoogle Scholar
- 21.Marur S, Li S, Cmelak AJ, et al. E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx—ECOG-ACRIN Cancer Research Group. J Clin Oncol. 2017;35:490–7.CrossRefGoogle Scholar